NASDAQ
9 days, 11 hours ago 
BGNE
Beigene, LTD
Form 4: BeOne Medicines Global Head of R&D Reports Sale of Shares for Tax Withholding
BeOne Medicines Ltd.'s Global Head of R&D, Wang Lai, reported a sale of 1,028 American Depositary Shares (ADS) at $260 per share, primarily to cover tax obligations related to the vesting of restricted share units.
NASDAQ
9 days, 11 hours ago 
BGNE
Beigene, LTD
Form 4: BeOne Medicines COO Sells Shares for Tax Withholding
BeOne Medicines Ltd.'s President and COO, Xiaobin Wu, sold 1,363 American Depositary Shares for $260 each to cover mandatory tax withholding related to a restricted share unit award.
NASDAQ
9 days, 11 hours ago 
BGNE
Beigene, LTD
Form 4: BeOne Medicines Director Sells Over 2,000 ADSs Under Pre-Arranged Trading Plan
Xiaodong Wang, a Director and 10% Owner of BeOne Medicines Ltd., executed sales of 2,007 American Depositary Shares (ADS) on June 24, 2025, through a Rule 10b5-1 trading plan.
NASDAQ
9 days, 11 hours ago 
BGNE
Beigene, LTD
Form 4: BeOne Medicines CEO John Oyler Sells Shares for Tax Withholding
BeOne Medicines Ltd. CEO John Oyler reported the sale of American Depositary Shares totaling approximately $830,989.96 for mandatory tax withholding purposes related to the vesting of restricted share units.
NASDAQ
16 days, 11 hours ago 
BGNE
Beigene, LTD
Form 4: BeOne Medicines SVP Sells Shares for Tax Withholding Upon RSU Vesting
BeOne Medicines Ltd.'s SVP and General Counsel, Chan Henry Lee, sold 422 American Depositary Shares on June 16, 2025, to cover mandatory tax withholding related to the vesting of restricted share units.
NASDAQ
16 days, 11 hours ago 
BGNE
Beigene, LTD
Form 4: BeOne Medicines Global Head of R&D Reports Share Sales for Tax Withholding
Wang Lai, Global Head of R&D at BeOne Medicines Ltd., reported the sale of American Depositary Shares (ADS) totaling 1,647 units over two days in June 2025, primarily to cover tax withholding obligations related to vested restricted share units.
Capital raise
 
NASDAQ
16 days, 11 hours ago 
BGNE
Beigene, LTD
Form 4: BeOne Medicines COO Sells Shares for Tax Withholding Following RSU Vesting
BeOne Medicines Ltd.'s President and COO, Wu Xiaobin, sold a total of 2,173 American Depositary Shares across two days in June 2025 to cover tax obligations related to the vesting of restricted share units.
NASDAQ
16 days, 11 hours ago 
BGNE
Beigene, LTD
Form 4: BeOne Medicines CEO John Oyler Reports Routine Share Sales for Tax Withholding
BeOne Medicines Ltd. CEO John Oyler reported sales of American Depositary Shares on June 16 and June 17, 2025, primarily to cover mandatory tax withholding obligations related to restricted share unit vesting.
NASDAQ
22 days, 10 hours ago 
BGNE
Beigene, LTD
Form 4: BeOne Medicines Principal Accounting Officer Reports Equity Compensation and Tax-Related Share Sale
BeOne Medicines' Principal Accounting Officer, Titus B. Ball, reported the acquisition of 29,601 ordinary shares as restricted share units and the sale of 134 American Depositary Shares for tax withholding purposes.
NASDAQ
22 days, 10 hours ago 
BGNE
Beigene, LTD
Form 4: BeOne Medicines Grants Significant Equity Awards to SVP, General Counsel
BeOne Medicines Ltd. has granted its Senior Vice President and General Counsel, Lee Chan Henry, a substantial package of restricted share units and share options, aligning executive incentives with long-term company performance.
BGNE 
Beigene, LTD 
NASDAQ

Form 4: BeOne Medicines Global Head of R&D Reports Share Sales for Tax Withholding

Sentiment:
 Insider Transaction Report
 18 June 2025 5:10 PM

Wang Lai, Global Head of R&D at BeOne Medicines Ltd., reported the sale of American Depositary Shares (ADS) totaling 1,647 units over two days in June 2025, primarily to cover tax withholding obligations related to vested restricted share units.

Capital raise
  The document references an 'RMB Shares Employee Participation Plan' through which certain executive officers and qualified employees, including the Reporting Person, indirectly purchased RMB Shares directly from the Issuer in its initial public offering on the STAR Market.  The plan purchased an aggregate of 2,069,546 RMB Shares directly from the Issuer at the initial public offering price of RMB192.6 per RMB Share.  The Reporting Person contributed RMB10 million to this plan, indicating a capital inflow to the company specifically for this employee program. 

Summary
  • Wang Lai, Global Head of R&D, Director, and 10% Owner of BeOne Medicines Ltd. (ONC), filed a Form 4 detailing recent equity transactions.
  • On June 16, 2025, Wang Lai sold 1,177 American Depositary Shares (ADS) at a weighted average price of $266.404 per ADS.
  • On June 17, 2025, an additional 470 ADSs were sold at a price of $251.365 per ADS.
  • These sales, totaling 1,647 ADSs, were conducted to satisfy mandatory tax withholding provisions associated with the vesting of previously granted restricted share unit (RSU) awards.
  • Following these transactions, Wang Lai directly holds 1,036,893 Ordinary Shares and indirectly holds 731,965 Ordinary Shares through Wang Holdings LLC.
  • Wang Lai also has an indirect economic interest in an indeterminable portion of RMB Shares held by the RMB Shares Employee Participation Plan, having contributed RMB10 million to the plan, which purchased 2,069,546 RMB Shares at RMB192.6 per share (approximately $30.1295).
Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive because the reported sales by the Global Head of R&D were for mandatory tax withholding purposes, which is a common and non-discretionary reason for insider sales. The executive retains substantial direct and indirect equity in the company, indicating continued alignment with company performance. The mention of the RMB Shares Employee Participation Plan also highlights an internal capital inflow mechanism.

Positives
  • The sales were explicitly for mandatory tax withholding, indicating a non-discretionary reason rather than a lack of confidence in the company's future.
  • The executive retains significant direct and indirect equity holdings in BeOne Medicines, demonstrating continued alignment with shareholder interests.
  • The existence of an employee participation plan for RMB Shares suggests a mechanism to align employee incentives with company performance.
Negatives
  • The sale of shares by a high-ranking insider, even for tax purposes, reduces their direct equity stake in the company.
  • The price of the second ADS sale ($251.365) was lower than the first ($266.404), indicating a slight decrease in the ADS price over the two-day transaction period.
Future Outlook

NA

Industry Context

This Form 4 filing details routine insider transactions for tax purposes and does not provide broader industry context or trends. It is specific to the equity holdings and transactions of a key executive at BeOne Medicines Ltd.

Stakeholder Impact
  • Shareholders: The sale of shares by a key executive, even for tax purposes, could be perceived negatively by some, but the non-discretionary nature and retained significant holdings mitigate major concern. The existence of an employee share plan could be seen positively as it aligns employee interests with company performance.
  • Employees: The RMB Shares Employee Participation Plan allows certain executive officers and qualified employees to indirectly participate in the company's STAR Offering, providing an incentive and ownership opportunity.
Next Steps
  • Continued vesting of restricted share units on each anniversary of June 15, 2023, and June 16, 2021, subject to continued service.
  • Potential accelerated vesting of unvested securities upon certain termination events.
Related Party Transactions
  • The indirect ownership of 731,965 Ordinary Shares through Wang Holdings LLC, where the Reporting Person's spouse and a trust for spouse and children are also owners, constitutes a related party holding.
  • The Reporting Person's participation and contribution of RMB10 million to the RMB Shares Employee Participation Plan, which purchased shares directly from the Issuer, represents a related party transaction.
Key Dates
  • 06/16/2021: Anniversary date for vesting of restricted share units related to the 06/17/2025 sale.
  • 06/15/2023: Anniversary date for vesting of restricted share units related to the 06/16/2025 sale.
  • 06/16/2025: Date of earliest transaction; sale of 1,177 American Depositary Shares.
  • 06/17/2025: Sale of 470 American Depositary Shares.
  • 06/18/2025: Date the Form 4 was signed.
Keywords
BeOne Medicines Ltd., ONC, SEC Form 4, Insider Trading, Stock Sale, Restricted Share Units, Tax Withholding, Wang Lai, American Depositary Shares, RMB Shares, Employee Participation Plan, Corporate Officer, Director, 10% Owner
BGNE 
Beigene, LTD 
NASDAQ
Sector: TBD
 
Filings with Classifications
Capital raise
18 June 2025 5:10 PM
Insider Transaction Report
  • The document references an 'RMB Shares Employee Participation Plan' through which certain executive officers and qualified employees, including the Reporting Person, indirectly purchased RMB Shares directly from the Issuer in its initial public offering on the STAR Market.
  • The plan purchased an aggregate of 2,069,546 RMB Shares directly from the Issuer at the initial public offering price of RMB192.6 per RMB Share.
  • The Reporting Person contributed RMB10 million to this plan, indicating a capital inflow to the company specifically for this employee program.
Capital raise
21 May 2025 4:45 PM
8-K Filing
  • The company has been granted a share issue mandate to the Board of Directors to issue, allot or deal with unissued ordinary shares and/or American Depositary Shares (ADSs) (including any sale or transfer of treasury shares out of treasury) not exceeding 20% of the total number of issued shares of the Company (excluding treasury shares) as of the date of passing of such ordinary resolution up to the next annual general meeting of shareholders of the Company, subject to the conditions described in the Proxy Statement (the General Mandate to Issue Shares).
Worse than expected
13 May 2025 8:15 PM
Shareholder Ownership Change
  • The filing indicates that HHLR Advisors and Hillhouse Investment Management have reduced their stake in BeiGene, Ltd. to 4.9% and have filed an 'exit filing', signifying their intention to no longer report their holdings on Schedule 13D.
  • A fund managed by HHLR sold 16,000,000 Ordinary Shares in a block trade, which represents a substantial divestment by a key institutional investor.
  • While the filing is a disclosure of a transaction, the reduction of a significant stake by a major investor can be interpreted by the market as a negative signal regarding the company's future prospects or the investor's portfolio strategy.
Better than expected
7 May 2025 6:09 AM
Quarterly Report (Form 10-Q)
  • The company achieved GAAP profitability, a significant improvement from the prior-year period loss.
  • Revenue growth was strong, driven by Brukinsa sales.
  • Operating cash flow improved.
Better than expected
7 May 2025 6:04 AM
Earnings Release
  • The company achieved GAAP profitability for the first time.
  • Revenue growth significantly exceeded expectations.
  • BRUKINSA sales demonstrated strong performance and market share gains.
Better than expected
29 April 2025 5:03 PM
Current Report
  • BeiGene successfully invalidated the patent claims against BRUKINSA, removing a potential legal hurdle.
Capital raise
7 April 2025 10:07 AM
Proxy Statement
  • The company is seeking approval for a share issue mandate to issue, allot or deal with unissued ordinary shares and/or American Depositary Shares (ADSs) not exceeding 20% of the total number of issued shares of the Company.
  • The company is seeking approval to allocate to Amgen Inc. up to a maximum amount of shares in order to maintain the same shareholding percentage of Amgen.
Capital raise
7 April 2025 6:03 AM
Proxy Statement
  • The company is seeking shareholder approval for a general mandate to issue shares, allowing the Board of Directors to issue up to 20% of the company's outstanding shares.
  • The company is seeking shareholder approval for a connected person placing authorization, allowing the company to allocate shares to Amgen in securities offerings to maintain its shareholding percentage.
Better than expected
7 April 2025 6:03 AM
Proxy Statement
  • The company's revenue growth is expected to outpace costs in 2025.
  • The company anticipates positive GAAP operating income and cash flow generation from operations in 2025.
  • BRUKINSA generated $2.6 billion in global revenue in 2024, a 105% increase from the prior year.
Worse than expected
4 March 2025 2:30 AM
Beneficial Ownership Amendment
  • The sale of a significant block of 2,480,000 ADSs by HHLR Fund, a major investor, indicates a reduction in their stake, which is generally perceived as a negative signal by the market.
Worse than expected
28 February 2025 9:28 PM
SEC Form 4 Filing
  • The document contains worse than expected results because a major shareholder is selling a significant number of shares, which could indicate a lack of confidence in the company's future prospects.
Delay expected
27 February 2025 6:12 AM
Annual Results
  • The FDA deferred approval for tislelizumab in first-line unresectable, recurrent, locally advanced, or metastatic ESCC on account of a delay in scheduling clinical site inspections.
Better than expected
27 February 2025 6:04 AM
Earnings Release
  • The company's revenue growth exceeded expectations, driven by strong BRUKINSA sales.
  • BeiGene narrowed its GAAP operating loss and achieved positive non-GAAP operating income, indicating improved profitability.
  • The company's 2025 revenue guidance suggests continued growth and profitability.
Better than expected
13 January 2025 5:02 PM
Financial Guidance
  • The company's expectation of positive operating income is better than the typical financial performance of a development stage biotechnology company.
Worse than expected
10 December 2024 9:25 PM
SEC Form 4 Filing
  • The document details a significant sale of shares by a major shareholder, which is generally considered a negative signal.
Better than expected
12 November 2024 6:06 AM
Quarterly Report
  • The company's revenue growth exceeded expectations, driven by strong sales of BRUKINSA.
  • The company's net loss improved compared to the same period last year, indicating progress towards profitability.
  • The company's pipeline development is progressing faster than expected, with eight new molecular entities entering clinical trials year-to-date.
Delay expected
12 November 2024 6:06 AM
Quarterly Report
  • The FDA deferred approval for tislelizumab in first-line unresectable, recurrent, locally advanced, or metastatic ESCC on account of a delay in scheduling clinical site inspections.
Better than expected
12 November 2024 6:03 AM
Quarterly Report
  • The company's non-GAAP operating income of $66 million is significantly better than the $16 million loss in the same period last year.
  • BRUKINSA sales growth of 87% in the US and 217% in Europe exceeded expectations.
  • The company's pipeline expansion with four new molecular entities entering clinical trials is a positive development.
Worse than expected
30 September 2024 6:02 AM
Risk Factor Update
  • The document highlights significant financial risks, including continued net losses and the need for additional financing, indicating worse than expected financial performance.
  • The document details numerous operational and regulatory challenges, suggesting a more difficult path to profitability than might have been anticipated.
Capital raise
30 September 2024 6:02 AM
Risk Factor Update
  • The document states that BeiGene may need to obtain additional financing to fund its operations.
  • The company may seek funding through public or private offerings, debt financing, collaboration and licensing arrangements, or other sources.
  • The document also mentions that raising additional capital may cause dilution to shareholders.
Delay expected
30 September 2024 6:02 AM
Risk Factor Update
  • The document mentions delays in regulatory approvals for tislelizumab due to the inability to complete inspections.
  • The document also notes that clinical trials may be delayed due to difficulties in patient enrollment.
Better than expected
7 August 2024 6:07 AM
Quarterly Report
  • The company's revenue growth exceeded expectations, driven by strong sales of BRUKINSA and other products.
  • The company achieved positive adjusted operating income, a significant improvement over previous quarters.
  • The company's gross margin on product sales increased to 85.0%, indicating improved profitability.
Capital raise
7 August 2024 6:07 AM
Quarterly Report
  • The company may need to obtain additional financing to fund its operations.
  • The company has filed a shelf registration statement with the SEC for the issuance of an unspecified amount of securities.
Delay expected
7 August 2024 6:07 AM
Quarterly Report
  • The FDA has deferred approval for tislelizumab in first-line unresectable, recurrent, locally advanced, or metastatic ESCC on account of a delay in scheduling clinical site inspections.
Better than expected
7 August 2024 6:04 AM
Quarterly Report
  • The company achieved non-GAAP operating income, which was better than the expected loss.
  • The company's revenue growth, particularly for BRUKINSA, was significantly higher than expected.
  • The company's GAAP operating loss decreased by 66%, which was better than expected.
Delay expected
7 August 2024 6:04 AM
Quarterly Report
  • The U.S. FDA deferred approval for tislelizumab in first-line ESCC due to a delay in scheduling clinical site inspections.
Capital raise
5 June 2024 4:35 PM
Annual General Meeting Results
  • The company received approval for a general mandate to issue shares, not exceeding 20% of the total number of issued ordinary shares.
  • The company also received authorization to allocate shares to Baker Bros. Advisors LP, Hillhouse Capital Management, Ltd., and Amgen Inc. to maintain their shareholding percentages, which could involve a capital raise.
Capital raise
8 May 2024 6:09 AM
Quarterly Report
  • The company may need to obtain additional financing to fund its operations.
  • The company has a shelf registration statement with the SEC for the issuance of an unspecified amount of securities.
  • The company may seek additional funding through a combination of equity offerings, debt financings, collaboration agreements, strategic alliances, licensing arrangements, government grants, and other available sources.
Better than expected
8 May 2024 6:09 AM
Quarterly Report
  • The company's revenue growth and improved gross margin exceeded expectations.
  • The company's net loss was lower than the same period last year, indicating progress towards profitability.
Better than expected
8 May 2024 6:06 AM
Quarterly Report
  • The company's revenue growth significantly exceeded expectations, driven by strong sales of BRUKINSA.
  • The company's operating losses improved more than expected, indicating progress towards profitability.
  • The company achieved key regulatory approvals and pipeline advancements, exceeding expectations.
Delay expected
8 May 2024 6:06 AM
Quarterly Report
  • The pending FDA approval for tislelizumab in first-line unresectable ESCC may be deferred due to a potential delay in scheduling clinical site inspections.
Capital raise
26 April 2024 4:16 PM
Proxy Statement
  • The document includes a proposal for a general mandate to issue shares and/or ADSs, not exceeding 20% of the total number of issued shares.
  • The document includes proposals to authorize the allocation of shares to existing shareholders (Baker Bros. Advisors LP and Hillhouse Capital Management, Ltd.) and Amgen Inc. to maintain their shareholding percentages in future offerings.
Better than expected
23 April 2024 4:13 PM
Regulatory Approval Announcement
  • The European Commission approval for tislelizumab is a positive development and better than expected as it expands the market for the drug and validates its efficacy in treating NSCLC.
Better than expected
15 March 2024 4:52 PM
Drug Approval Announcement
  • The RATIONALE 302 trial showed a statistically significant and clinically meaningful survival benefit for TEVIMBRA compared to chemotherapy, with a median overall survival of 8.6 months versus 6.3 months.
Better than expected
26 February 2024 6:02 AM
Annual Results
  • The company's revenue growth of 74% for the full year and 67% for the quarter exceeded expectations.
  • The 129% growth in BRUKINSA sales was significantly better than anticipated.
  • The reduction in operating losses was better than the prior year.

Disclaimer: This summary was generated by artificial intelligence and its accuracy is not guaranteed. The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.